News Author: Andrew D. Bowser Publish date: June 16, 2018
A new study finds a strong link between making prescription opioids harder to get and a surge in dark web sales.
News Author: Andrew D. Bowser Publish date: June 14, 2018
Stricter blood management practices and VTE prophylaxis may be needed if the study findings are confirmed.
News Author: Andrew D. Bowser Publish date: June 12, 2018
Thyroid dysfunction early in pregnancy may increase risk of gestational diabetes.
News Author: Andrew D. Bowser Publish date: June 12, 2018
More research is needed to pinpoint the link between fluconazole use and risks to neonates.
News Author: Andrew D. Bowser Publish date: June 12, 2018
Use of common medications with depression as a possible side effect has public health implications.
News Author: Andrew D. Bowser Publish date: June 12, 2018
About one in three patients had lack of fill approval by insurers.
News Author: Andrew D. Bowser Publish date: June 11, 2018
CHICAGO—bb2121, the anti-BCMA chimeric antigen receptor (CAR) T-cell therapy, induced deep and durable ongoing responses in heavily pretreated multipl...
News Author: Andrew D. Bowser Publish date: June 10, 2018
With the right education tool, patients can gain knowledge about their disease.
News Author: Andrew D. Bowser Publish date: June 8, 2018
CHICAGO – The drug combination was evaluated in a phase 2 study of patients with previously untreated CLL.
News Author: Andrew D. Bowser Publish date: June 8, 2018
CHICAGO—Polatuzumab vedotin, when added to bendamustine (B) and rituximab (R), significantly improved response and survival rates in a cohort of pa...
News Author: Andrew D. Bowser Publish date: June 7, 2018
CHICAGO – Could lenalidomide plus rituximab be a first-line option?
News Author: Andrew D. Bowser Publish date: June 7, 2018
CHICAGO—Two agents targeting novel pathways in myeloid malignancies—mivebresib and bencentinib—are showing promise in early studies, according to a sp...
News Author: Andrew D. Bowser Publish date: June 6, 2018
CHICAGO – Treatment with Hu5F9-G4 (5F9) produced “encouraging” antitumor activity in a phase 1b study of 22 patients.
News Author: Andrew D. Bowser Publish date: June 6, 2018
In the first systematic review and meta-analysis to look at the link between smoking and outcomes after localized prostate cancer primary therapy, ...
News Author: Andrew D. Bowser Publish date: June 6, 2018
CHICAGO—Acalabrutinib monotherapy was highly effective in Waldenström’s macroglobulinemia (WM) in a phase 2 study, investigator Roger Owen, MD, report...
